JSB Market Research: Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022


Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Grnenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Grnenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain.

Browse Full Report @


- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cebranopadol for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cebranopadol performance
- Obtain sales forecast for Cebranopadol from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

  Table of Contents:

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 12
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 14
3.1.1 Painful Diabetic Neuropathy 16
3.1.2 Postherpetic Neuralgia 17
3.1.3 Trigeminal Neuralgia 17
3.2 Etiology and Pathophysiology 18
3.2.1 Etiology 19
3.2.2 Pathophysiology 20
4 Disease Management 28
4.1 Diagnosis and Treatment Overview 28
4.1.1 Diagnosis 28
4.1.2 Treatment Overview and Guidelines 35
5 Competitive Assessment 45
5.1 Overview 45

List of Tables

Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage 14
Table 2: Signs and Symptoms of NP 15
Table 3: Screening Tools for NP 29
Table 4: NP-Related Signs and Symptoms 31
Table 5: Treatment Guidelines for NP 36
Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy 42
Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012 44
Table 8: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013 47
Table 9: Select Products Used for NP Treatment, 2013 49
Table 10: Unmet Need and Opportunity in NP 51

List of Figures

Figure 1: Nociceptive Versus Neuropathic Pain 13
Figure 2: Etiology and Pathophysiology of NP 18
Figure 3: Pain Pathway - Somatosensory System 21
Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System 25
Figure 5: Pathophysiological Targets of NP Drugs 26
Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP 32
Figure 7: General Treatment Algorithm for NP 41
Figure 8: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022 66

For More Related Market Research Reports click here:

Global Wheelchair Market to 2018 - Market Size, Growth, and Forecasts in 50 Countries

Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018

About JSB Market Research -

JSB Market Research is one of the most significant databases of online market researches and intelligence reports and services. We specialize in providing market research reports for various industries. The online portal for marketing research deals with access to global market data and assists in providing expert insights and exposure on global companies, industries, products and trends.


Tel: + 91 - 22 – 41236650